Tuesday, October 16, 2018 - 07:00
  • Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and cetuximab on Monday, October 22, 4pm CEST (10 am EDT)

 

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that updated data from ongoing clinical trials evaluating lead asset, monalizumab, partnered with AstraZeneca/MedImmune, will be presented at the ESMO  2018 Congress in Munich, Germany, October 19-23, 2018. Eric Vivier, Chief Scientific Officer, is invited to the ESMO Congress as speaker in the Early detection of cancer using minimally invasive biomarkers Special Symposium.

 

 

A KOL call will be held Monday, October 22, at 4pm CEST (10 am EDT)

Dial in numbers:

France and International: +33 (0)1 72 72 74 03       US only: +1 646 722 4916

PIN code: 69616804#

The presentation will be made available on the Company’s website 30 minutes before the conference begins.

A replay will be available on Innate Pharma’s website after the conference call.

 

 

 

Posters and presentation details:

  • Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
  • Date and time: October 20, 2018, 15:00
  • Presentation number: 1049PD
  • Session: Poster Discussion session – Head and neck
  • Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
  • Location: Hall B3 – Room 23, ICM München, Munich, Germany

 

  • Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
  • Date & time: October 20, 2018, 12:30
  • Presentation number: 1194P
  • Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
  • Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
  • Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany

 

  • Title: Changes in the innate immune system as early events in cancer
  • Date & time: October 22, 2018, 15:05 – 15:25
  • Session: Special Symposium
  • Session Name: Early detection of cancer using minimally invasive biomarkers
  • Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
  • Location: Hall A1 – Room 17, ICM München, Munich, Germany

 

The posters will be made available on the Company’s website after the session.

AttachmentSize
PR in English126.75 KB
CP en français106.86 KB